Core Insights - Emory Healthcare has successfully performed the world's first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer using Microbot Medical's LIBERTY® Endovascular Robotic System, showcasing the system's versatility across various medical procedures [1][3][4] Company Overview - Microbot Medical is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY® Endovascular Robotic System being the first FDA-cleared single-use, remotely operated robotic solution designed for precision, efficiency, and safety [10] Product Details - The LIBERTY System allows for minimally invasive treatments, improving efficiency in reaching treatment sites within blood vessels due to its fine motor control capabilities [5] - The system is designed to reduce radiation exposure and physical strain on clinicians while enhancing procedural efficiency [7] Market Potential - The LIBERTY System aims to establish endovascular robotic navigation as the standard of care for PAE in patients with enlarged prostates, similar to the adoption of robotic-assisted prostatectomy for prostate cancer [4] - Approximately 40 million men in the U.S. are affected by BPH, indicating a significant patient population for the LIBERTY System [2] Recent Developments - Microbot Medical commenced the Limited Market Release of the LIBERTY system in November 2025 and plans for a Full Market Release at the Society of Interventional Radiology conference in April 2026, aiming to deepen market adoption [8]

Core Insights - The publication of an article in the Journal of Vascular and Interventional Radiology highlights the quality and impact of the study related to the LIBERTY Endovascular Robotic System [1][2] - The company aims to expand evidence-based data to support broader commercial adoption of the LIBERTY system [1] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology [5] - The LIBERTY Endovascular Robotic System is the world's first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency, and safety [5] Study Details - The article provides a comprehensive analysis of the ACCESS-PVI study, which was completed in 2025 and presented at the Society of Interventional Radiology annual meeting [3] - The LIBERTY system received FDA clearance in September 2025 for peripheral endovascular procedures [3] Market Strategy - The company commenced limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology conference in April 2026 [4] - The goal is to showcase LIBERTY to deepen market adoption [4]

Core Insights - Microbot Medical Inc. announced that CEO Harel Gadot will participate as a panelist at The Surgical Disruptive Technology Summit, part of SAGES NBT Innovation Weekend, from February 19-21, 2026, in Houston, TX [1] - The summit aims to foster dialogue between industry and providers on innovations in surgical technology, focusing on minimally invasive interventions [2] Company Overview - Microbot Medical is a commercial stage medical device company dedicated to transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY® Endovascular Robotic System is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [4] Product Features and Market Strategy - The LIBERTY System is designed to enhance access, safety, and clinical outcomes in vascular care, featuring remote interventions and precision navigation [2] - The company commenced limited market release of the LIBERTY system in late 2025 and plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [3] - LIBERTY's single-use, compact design aims to eliminate barriers to broader adoption of surgical robotics, positioning it as a new class of surgical robotics [3]

Core Insights - Microbot Medical Inc. is progressing towards a Full Market Release (FMR) of its LIBERTY® Endovascular Robotic System in Q2 2026, building on positive customer feedback and market enthusiasm [1] - The company achieved significant milestones in 2025, including FDA 510(k) clearance and the initiation of a limited market release [1][4] - The target market for LIBERTY includes approximately 2.5 million peripheral endovascular procedures annually in the U.S. [1] 2025 Operational and Business Achievements - Received FDA clearance for the LIBERTY system, the first single-use, remotely operated robotic system for peripheral endovascular procedures [4] - Launched a Limited Market Release, with Emory University Hospital being the first to adopt the system [4] - Established a commercial leadership team and expanded cross-functional teams to support launch readiness [4] - Presented pivotal trial data showing 100% robotic navigation success and a 92% reduction in radiation exposure [4] - Expanded the intellectual property portfolio with 20 patents granted and 52 applications pending [4] Anticipated 2026 Operational and Commercial Milestones - Full Market Release of the LIBERTY System is set for Q2 2026, coinciding with the Society of Interventional Radiology conference [3][4] - Plans to grow the customer base by attracting early adopters and securing new hospitals for medium-to-high volume procedures [3] - Aims to validate the LIBERTY System's market opportunity by expanding the types of procedures and end-user call points [3] - Establish commercial infrastructure for expansion into international markets [3] - Maintain a strong presence at key medical societies and conferences throughout 2026 [5]

Core Insights - Microbot Medical Inc. has announced the commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, marking a significant milestone in the introduction of single-use robotic systems for peripheral endovascular procedures [1][2] - The Limited Market Release (LMR) will focus on high procedure volume regions to gather real-world insights and prepare for a Full Market Release (FMR) expected at the Society of Interventional Radiology meeting in April 2026 [1][2] Company Developments - The company has established a core commercial team and secured a third-party logistics partner to support the LMR of LIBERTY® [2] - Positive feedback from physicians and hospital administrators has validated the decision to proceed with the limited market release [1][2] Product Overview - LIBERTY® is the first FDA cleared single-use, remotely operated robotic system designed for precision, efficiency, and safety in endovascular procedures [3] - The product is backed by a strong intellectual property portfolio and a commitment to innovation, positioning Microbot Medical as a leader in the endovascular care market [3]

Core Insights - Microbot Medical Inc. has received its first patent in Japan for the LIBERTY® Endovascular Robotic System, enhancing its intellectual property portfolio [1] - The U.S. FDA granted marketing clearance for the LIBERTY® System on September 8, 2025, prompting the company to accelerate its commercial launch plans targeting 2.5 million peripheral endovascular procedures annually in the U.S. [2] - The company is focusing on the U.S. market while exploring opportunities in other global markets, particularly Japan, which may expedite local approval and adoption of its technology [3] Company Overview - Microbot Medical Inc. is a medical device company specializing in advanced robotic technology aimed at transforming endovascular procedures [3] - The LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety [3] - The company is committed to innovation and has a strong intellectual property portfolio to support its growth [3]

Core Insights - Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System, marking a significant milestone for the company in the commercialization of this innovative medical device [2][3] - The CEO, Harel Gadot, will discuss the implications of this FDA clearance and the company's commercialization plans during a live interview on Benzinga All Access [1] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with the LIBERTY® Endovascular Robotic System being the first single-use, remotely operated robotic solution designed for precision and efficiency [3] - The company is backed by a strong intellectual property portfolio and is committed to innovation in the field of endovascular care [3]

Core Viewpoint - Microbot Medical Inc. has entered into definitive agreements to exercise preferred investment options, allowing the purchase of up to 13,989,115 shares of common stock, with the offering expected to close in two tranches [1][2]. Group 1: Offering Details - The first closing of the offering is anticipated on or about September 16, 2025, involving the exercise of options for 12,064,627 shares at prices between $1.50 and $2.13 per share [2]. - The second closing is expected by October 15, 2025, for 1,924,488 shares at an exercise price of $2.10 per share [2]. - New unregistered short-term series J preferred investment options will be issued in connection with the cash exercise of these options, with an exercise price of $4.50 per share [2]. Group 2: Financial Proceeds - Gross proceeds from the first closing are projected to be approximately $25.2 million, while the second closing is expected to yield around $4 million [4]. - If fully exercised, the new short-term series J preferred investment options could generate additional gross proceeds of approximately $63 million [4]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for the development, commercialization, and regulatory activities of the LIBERTY® Robotic System, potential acquisitions, and general corporate purposes [4]. Group 4: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY® Endovascular Robotic System being a key product [8].

Core Insights - Microbot Medical Inc. has received a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority to enhance its manufacturing capabilities for the LIBERTY® Endovascular Robotic System, pending FDA marketing clearance [1][2][3] Group 1: Company Developments - The grant is expected to strengthen the company's balance sheet and operational readiness as it awaits FDA's decision on marketing clearance [3] - The Israel Innovation Authority recognized the company's recent achievements, the target market's size, the competitive advantages of a single-use robot, and the expected benefits to healthcare systems [2] - The LIBERTY® System is an investigational device currently pending FDA 510(k) clearance and is not available for sale in the U.S. [3][4] Group 2: Market Positioning - Microbot Medical aims to redefine endovascular robotics and improve care quality for patients globally with its single-use, fully disposable robotic system [4] - The company believes the grant validates its technology and reflects the IIA's confidence in its ability to scale manufacturing and meet business objectives [2][3]

Core Insights - Microbot Medical Inc. is expanding its commercial team in anticipation of the U.S. launch of the LIBERTY Endovascular Robotic System, projected for the third quarter of 2025 [1][2] - The company is actively engaged with the FDA, expecting a 510(k) decision during the third quarter of this year, which aligns with the FDA's original review timeline [1][4] - The addition of Michael Lytle as the head of Sales Operations & Analytics is aimed at enhancing sales infrastructure and optimizing the sales cycle [2][3] Company Developments - The LIBERTY System is currently under FDA review and is not available for sale in the U.S. until clearance is granted [4] - Michael Lytle's previous experience at ZOLL Cardiac Management Solutions is expected to contribute to the company's market targeting and resource allocation [3] - The company aims to redefine endovascular robotics and improve patient care through its innovative, single-use, fully disposable robotic system [5]